1 / 12

Neurofibromatosis 1- NF1

Neurofibromatosis 1- NF1. Gutmann et al. 2013. BIOL 445 Alexa Schulman. NF1 Negatively Regulates Ras. Rubin et al. 2005. NF1 is a GAP ( GTPase Activating Protein). Lodish et al. Fig. 20-5. NF1 is therefore a Tumor Suppressor. What does this mean ?. Gutmann et al. 2013.

brosh
Download Presentation

Neurofibromatosis 1- NF1

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Neurofibromatosis 1- NF1 Gutmann et al. 2013 BIOL 445 Alexa Schulman

  2. NF1 Negatively Regulates Ras Rubin et al. 2005

  3. NF1 is a GAP (GTPase Activating Protein) Lodish et al. Fig. 20-5

  4. NF1 is therefore a Tumor Suppressor • What does this mean? Gutmann et al. 2013

  5. NF1 codes for the cytoplasmic protein neurofibromin Gutmann et al. 2013

  6. Neurofibromin is necessary for many developmental pathways

  7. Activation of the RTK pathway leads to increased proliferation and motility of NF1-/- Schwann cells and astrocytes

  8. Tumor formation seems to require the presence of NF1+/- cells or another mutation such as TP53 Rubin et al. 2005

  9. There are many different types of tumors associated with NF1

  10. Neurofibromas are often numerous and removal can be tricky. Drugline.org

  11. NF1-/- cells have increased sensitivity to TRAIL Reuss et al. 2013

  12. References • Gutmann, David H., Jaishri O. Blakeley, Bruce R. Korf, and Roger J. Packer. "Optimizing Biologically Targeted Clinical Trials for Neurofibromatosis." Informa Healthcare: Expert Opinion (2013) • Reuss, David E., Jana Mucha, Christian Hagenlocher, Volker Ehemann, LanKluwe, Victor Mautner, and Andreas Von Deimling. "Sensitivity of Malignant Peripheral Nerve Sheath Tumor Cells to TRAIL Is Augmented by Loss of NF1 through Modulation of MYC/MAD and Is Potentiated by Curcumin through Induction of ROS." PLoS ONE 8.2 (2013) • Rubin, Joshua B., and David H. Gutmann. "Opinion: Neurofibromatosis Type 1 — a Model for Nervous System Tumour Formation?" Nature Reviews Cancer 5.7 (2005): 557-64. • Tong, James Jiayuan, Samuel E. Schriner, David McCleary, Brian J. Day, and Douglas C. Wallace. "Life Extension through Neurofibromin Mitochondrial Regulation and Antioxidant Therapy for Neurofibromatosis-1 in Drosophila Melanogaster." Nature Genetics 39.4 (2007): 476-85.

More Related